AnserBio

Nanoparticle based delivery of p53 protein - addressing the most frequent mutation in cancer. -

Active Seed Startup Nesher Founded 2017-01

Website ↗ LinkedIn

AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healt…